Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Valneva SE. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Valneva SE (“Valneva” or “the Company”) (NASDAQ: VALN). Investors who purchased Valneva securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Valneva has violated federal securities laws.
Valneva Investigation Details
On March 23, 2026, Valor and its development partner Pfizer Inc. issued a press release “announc[ing] topline results from the Phase 3 VALOR “Vaccine Against Lyme for Outdoor Recreationists” clinical trial (NCT05477524) of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA15)”. Although the two companies characterized the data as positive, the press release reported that the vaccine failed to meet its primary endpoint, citing a low incidence of disease cases. Following this news, Valneva’s American Depositary Receipt (“ADR”) price fell $3.83 per ADR, or 37.11%, to close at $6.49 on March 23, 2026.
What’s Next for Valneva Investors?
If you are aware of any facts relating to this investigation or purchased Valneva securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
VALN — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”